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Abstract
Introduction Endoglin (ENG) forms a receptor complex with ALK1 in endothelial cells (ECs) to promote BMP9/10 sig-
nalling. Loss of function mutations in either ENG or ALK1 genes lead to the inherited vascular disorder hereditary haem-
orrhagic telangiectasia (HHT), characterised by arteriovenous malformations (AVMs). However, the vessel-specific role 
of ENG and ALK1 proteins in protecting against AVMs is unclear. For example, AVMs have been described to initiate in 
arterioles, whereas ENG is predominantly expressed in venous ECs. To investigate whether ENG has any arterial involve-
ment in protecting against AVM formation, we specifically depleted the Eng gene in venous and capillary endothelium whilst 
maintaining arterial expression, and investigated how this affected the incidence and location of AVMs in comparison with 
pan-endothelial Eng knockdown.
Methods Using the mouse neonatal retinal model of angiogenesis, we first established the earliest time point at which Apj-
Cre-ERT2 activity was present in venous and capillary ECs but absent from arterial ECs. We then compared the incidence 
of AVMs following pan-endothelial or venous/capillary-specific ENG knockout.
Results Activation of Apj-Cre-ERT2 with tamoxifen from postnatal day (P) 5 ensured preservation of arterial ENG protein 
expression. Specific loss of ENG expression in ECs of veins and capillaries led to retinal AVMs at a similar frequency to 
pan-endothelial loss of ENG. AVMs occurred in the proximal as well as the distal part of the retina consistent with a defect 
in vascular remodelling during maturation of the vasculature.
Conclusion Expression of ENG is not required in arterial ECs to protect against AVM formation.
Keywords Arteriovenous malformation · Hereditary haemorrhagic telangiectasia · Acvrl1 · Retinal angiogenesis · Notch
Background
Endoglin (ENG) is a glycosylated transmembrane protein 
primarily expressed on endothelial cells (ECs). Although 
originally thought to be a co-receptor for TGFbeta1, it is 
now known to have a much higher affinity for BMP9 and 
BMP10 ligands [1]. ENG can accumulate BMP9/10 ligand 
on the EC surface and supports ligand binding to the signal-
ling receptor ALK1 (also known as ACVRL1) leading to 
SMAD1/5/8 phosphorylation and a range of downstream 
transcriptional responses [2–4]. Loss of function mutations 
in either ENG or ALK1 genes account for the vast majority 
of cases of hereditary haemorrhagic telangiectasia (HHT). 
This is an inherited vascular disorder typified by small 
bleeding telangiectases in the oronasal mucosa and gas-
trointestinal tract, as well as larger high flow arteriovenous 
malformations (AVMs) in lung, liver or neural tissues lead-
ing to severe morbidity [5]. HHT type I (caused by ENG 
mutations) and HHT type 2 (caused by ALK1 mutations) 
are clinically very similar, except that HHT1 patients have 
a higher frequency of lung and brain AVMs, whilst HHT2 
patients have a higher incidence of gastrointestinal bleeding 
[5]. The reasons for this tissue bias is unknown.
HHT1 and HHT2 patients are heterozygous for mutations 
in ENG or ALK1 genes, respectively; although recent work 
has revealed that vascular lesions from HHT patients contain 
cells with a local second mutation in the ‘good’ allele (ENG 
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or ALK1). This finding supports the idea that a two genetic 
hit mechanism is required for vascular lesion formation in 
HHT [6]. Strong evidence from mouse models of HHT1 and 
HHT2 also supports this two-hit mechanism where complete 
endothelial loss of ENG or ALK1 protein is a pre-requisite 
for robust vascular lesion formation in response to angio-
genic stimuli [7]. In contrast, mice that are heterozygous 
for mutations (Eng+/− or Alk1+/−) have low penetrance of 
disease [8, 9].
It is well established from these studies that ENG and 
ALK1 proteins are required in ECs to protect the vascula-
ture from abnormal arteriovenous shunting of blood through 
AVMs due to aberrant vascular remodelling. However, it is 
not clear whether this is primarily due to a defect in arte-
rial or venous protective function, or both. ALK1 has been 
shown to be expressed primarily in adult arterial vessels [10] 
and loss of ALK1 in development leads to loss of expression 
of genes associated with arterial identity such as Efnb2 and 
Jag1 [11, 12]. This suggests an arterial specific function 
of ALK1 signalling. Furthermore, an arteriolar origin for 
AVMs has been visually described in the neonatal retina 
following mosaic loss of ENG in ECs [13], and an arterial 
defect was also suggested by the finding that some arterial 
markers such as Ephnb2 show reduced expression in the 
absence of ENG [13]. In addition, there has been a long-
standing debate whether AVMs in HHT are due to loss of 
arterial identity via disruption of the Notch pathway. There 
are three main lines of evidence for this idea: Notch ligands 
are predominantly expressed in arteries and are required 
to maintain arterial identity, loss of Notch activity leads to 
AVMs, and Notch signalling synergises with ALK1 signal-
ling [14–17]. Therefore, to address whether there is arterial 
involvement in the formation of AVMs in HHT, we depleted 
ENG specifically in venous and capillary ECs, leaving arte-
rial ENG expression intact. We then analysed AVM forma-
tion using the well-established neonatal mouse model of 
retinal angiogenesis.
Methods
The care and use of animals were in accordance with the UK 
Government Animals (Scientific Procedures) Act 1986 and 
were approved by Newcastle University’s Animal Welfare 
and Ethical Review Body. Engfl/fl mice[18] were intercrossed 
with Cdh5-Cre-ERT2 [19] or Apj-Cre-ERT2 [20] lines to 
permit pan-endothelial or venous/capillary-specific target-
ing of the ENG floxed allele, respectively. To map Apj-Cre-
ERT2 activation, we used the Rosa26-mTmG Cre reporter 
line [21] and treated neonates with a single subcutaneous 
injection of tamoxifen (Sigma, T5648) dissolved in peanut 
oil: ethanol (10:1) at postnatal day (P)2 (0.5 mg), P4 (0.5 
mg) or P5 (0.6 mg). To generate efficient recombination of 
the Eng floxed allele, pups were given 0.6 mg tamoxifen on 
consecutive days at P5 and P6. Retinas were then harvested 
at different time points as indicated in the main text.
Mouse neonatal retina analysis was performed using a 
similar approach to our earlier work [22] and described in 
detail elsewhere [23]. Essentially, following enucleation of 
the eye and dissection, the retina was imaged directly to 
record RFP and GFP staining under an M2 Axio-imager 
microscope using an Axiocam digital camera. Subsequently, 
retinas were subject to methanol fixation and staining with 
isolectin B4-Alexa488 (Life Technologies) and antibodies 
against ENG (anti-CD105 from eBioscience), and smooth 
muscle actin (anti-aSMA-Cy3 from Sigma Aldrich). Sec-
ondary anti-rat antibody conjugated to Alexa568 or Alexa 
647 (Life Technologies) was used to detect anti-CD105. 
Images were captured using an M2 axio-imager microscope 
(Zeiss) and staining intensity analysis was performed using 
Zen software. For depth coding, z-stack images of the pri-
mary and secondary plexus were colour coded according 
to the distance from the upper surface of the retina using 
Zen software. For all experiments, either one or both retinas 
from each pup were stained and data were analysed using 
Graphpad prism software.
Results
Our first goal was to establish a mouse model of angiogen-
esis in which arterial endoglin could be maintained whilst 
depleting ENG in venous and capillary ECs. The Apj-Cre-
ERT2 mouse line shows venous/capillary endothelial-spe-
cific expression and has been used successfully to track 
venous ECs in coronary vessel development [20]. However, 
to establish when Cre-ERT2 expression from the Apj pro-
moter becomes venous endothelial-specific during develop-
ment of the neonatal vascular retinal plexus, we used the 
Rosa26-mTmG Cre reporter mouse [21]. CRE-mediated 
recombination causes the mTmG reporter expression to 
switch from tomato red fluorescent protein (RFP) to green 
fluorescent protein (GFP) allowing localisation and timing 
of CRE activity to be determined. Treatment of Apj-Cre-
ERT2;R26-mTmG neonates with tamoxifen at different 
postnatal ages (up to and including P5) and retinal tissue 
analysis at P8 showed that tamoxifen treatment at P5 led 
to arterial ECs retaining RFP expression whilst venous and 
capillary ECs became GFP-positive due to CRE-mediated 
recombination of the R26-mTmG reporter (Supplementary 
Fig. S1). In contrast, neonates that had been injected with 
tamoxifen at earlier time points (P2 or P4) showed signifi-
cant GFP expression in the arteries reflecting arterial Apj-
Cre activity. Thus, P5 was the earliest time point at which 
Apj-Cre-ERT2 activation becomes specific to non-arterial 
ECs in the developing retina. This is in agreement with the 
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Fig. 1  Pan-endothelial or venous-capillary-specific loss of ENG 
expression leads to similar incidence and frequency of AVMs. a 
Control retina harvested at P11 show the normal radial distribution 
of arteries and veins, with intervening capillaries. b Loss of ENG 
in venous and capillary ECs in Eng-iKOv retinas leads to multiple 
AVMs (arrows). Scale bar = 500 µm. c Incidence of AVMs at P11 
is similar between Eng-iKOe (n = 06) and Eng-iKOv (n = 16) retinas 
and the mean number of AVMs per retina is 1.8 in Eng-iKOe neo-
nates and 2.5 in Eng-iKOv retinas. The frequency of P11 retinas that 
have AVMs is 67% (4/6) in Eng-iKOe neonates and 94% (15/16) in 
Eng-iKOv neonates. Data were analysed by unpaired t test. d Eng-
iKOe retinas were stained with isolectin and anti-ENG antibody. 
Pan-endothelial loss of ENG in Eng-iKOe retinas leads to AVM for-
mation. e Eng-iKOv retinas retain arterial ENG protein, but develop 
AVMs in a similar way to Eng-iKOe retinas. Scale bar = 50 µm. A 
artery, V vein, avm arteriovenous malformation
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previously reported age of P5 when Apj transcripts are lost 
from neonatal retinal arteries [24]. This timing is likely to be 
because it takes 5 days of postnatal retinal vascular develop-
ment for the arterial endothelium to become phenotypically 
established, combined with the fact that pre-existing venous 
ECs can contribute to the arterial endothelium during retinal 
development via a process of EC migration against blood 
flow [25, 26].
We have previously shown that pan-endothelial knockout 
of ENG (Eng-iKOe) using Engfl/fl;Cdh5-Cre-ERT2 neonates 
led to AVMs affecting 70% of Eng-iKOe retinas [22]. How-
ever, initiation of Eng depletion was at P2, which is sub-
stantially prior to the establishment of differentiated arteries 
and veins in the developing retina. Therefore, to establish 
the phenotype of pan-endothelial Eng knockout at the later 
time points required for arterial specific Apj-Cre activity, 
we first determined whether delivery of tamoxifen at P5 
and P6 to Engfl/fl;Cdh5-Cre-ERT2 neonates led to retinal 
AVMs. Harvesting the tissue at P8 revealed that ENG pro-
tein was only partially depleted (not shown), likely because 
the time between Cre-ERT2 mediated recombination of the 
Eng floxed gene and tissue harvest was insufficient to allow 
complete turnover of pre-existing ENG protein. We therefore 
repeated the experiment leaving additional time for ENG 
protein loss, this time harvesting retinas at P11. In this sce-
nario, tamoxifen activation of Engfl/fl; Cdh5-Cre-ERT2 led to 
efficient ENG protein knockdown and the proportion of Eng-
iKOe retinas with AVMs was 67% (Fig. 1c), similar to our 
previous findings [22]. To compare this outcome with the 
effect of retaining arterial ENG expression, whilst knocking 
out ENG in venous and capillary ECs, Engfl/fl; Apj-Cre-ERT2 
neonates were treated with tamoxifen at P5 and P6 and tissue 
was harvested at P11 to generate venous/capillary-specific 
Eng knockout (Eng-iKOv) mice. Immunostaining of Eng-
iKOv retinas confirms ENG protein depletion in capillar-
ies and veins, whilst ENG expression is retained in arteries 
(Fig. 1e). Over 90% of Eng-iKOv retinas show AVM forma-
tion (Fig. 1b, c), pointing to the absence of a role for arte-
rial ENG in protecting against AVM formation. Littermate 
Engfl/fl controls treated with tamoxifen retain ENG expres-
sion in all vessels and have no AVMs (Fig. 1a, d).
There were no detectable differences between the vascu-
lar phenotypes following venous-specific or pan-endothe-
lial loss of ENG and venous enlargement was pronounced 
“downstream” of the AVMs, likely in response to increased 
blood flow (Supplementary Fig. S2a). The most distal por-
tion of the arteries, where they branch to form capillaries 
close to the periphery, shows evidence of mTmG recom-
bination when Cre is activated at P5 (Supplementary Fig. 
S1a, b, c). Therefore, it was important to establish whether 
AVMs were preferentially located at the most distal part of 
the artery, where ENG expression was lost, or in the mid 
and proximal regions where ENG protein was retained. 
Measuring the position of each AVM with respect to the 
arterial distance from the centre of the retina, and comparing 
this with the arterial length where ENG protein expression 
was retained, we found that AVMs were primarily located 
in the mid and proximal regions of the retina, and adjacent 
to ENG expressing arteries (Fig. 2a, b, c). To investigate 
whether normal levels of ENG protein expression were 
maintained on the arterial side of these AVMs, we per-
formed immunofluorescence staining intensity analysis. 
This confirmed that ENG protein levels were unaffected in 
arteries of Eng-iKOv retinas compared with controls, whilst 
ENG was significantly reduced in capillaries, veins and 
AVMs (Fig. 2d). AVMs were muscularised (Fig. 2a) likely 
in response to increased blood flow, similar to our previous 
observations [22].
A potential complication at P11 is that branches of the 
upper vascular plexus have begun to migrate down into the 
retina to form the deeper vessel plexus [27, 28]. We therefore 
used depth coding to locate AVMs and confirmed they were 
in the primary plexus (Fig. 3). Also, as the primary plexus 
had already reached the retinal periphery by P8, prior to full 
ENG protein knockdown, and AVMs were mainly found in 
the mid-plexus region, this suggests that AVMs form in the 
remodelling vasculature of the Eng-iKOv retinas and are not 
dependent on active angiogenic processes at the leading edge 
of the developing vascular plexus.
Fig. 2  ENG expression is maintained on the arterial side of AVMs in 
Eng-iKOv retinas. a Vascular endothelial cells in P11 Eng-iKOv reti-
nas were identified using isolectin staining. These retinas show ENG-
positive arteries, whilst AVMs and capillaries show reduced ENG 
staining. AVMs and arteries also have vascular smooth muscle cov-
erage (aSMA). A total of 42 AVMs were analysed, and in all cases, 
ENG protein was maintained on the arterial side of the malformation 
(arrow). Scale bar = 20 µm. b Cartoon to illustrate the extent of ENG 
expression (red) in arteries measured from the centre of the retina to 
the site at which arterial ENG expression is lost (black dashed arrow), 
which is close to the vascular plexus edge. Arterial ENG expression 
extends beyond the point at which AVMs form (grey dashed arrow). 
Veins (v) and AVMs are shown in green, and capillaries in purple, 
with position of plexus edge (pe) marked (purple arrow). c The dis-
tance from the centre of the retina to the arterial site of each AVM 
was measured. This was compared with the arterial distance at which 
ENG expression is lost, and shows that AVMs originate from ENG 
expressing arteries and AVMs were primarily located in the mid-
plexus region. The distance to the plexus edge is shown to provide 
context for the analysis. The arterial origin of AVMs was signifi-
cantly closer to the centre of the retina than the site at which arterial 
ENG protein was lost (n = 16/group). Data were analysed by paired 
t-test. ****p < 0.0001. d ENG immunofluorescent staining intensity 
was measured in different vessel types in Eng-iKOv retinas at P11 
(n = 9). ENG protein is retained at control levels in Eng-iKOv arteries 
whether AVMs were present or not, but ENG protein is significantly 
reduced in veins, capillaries and AVMs. Data were analysed by one 
way ANOVA with Bonferroni correction for multiple comparisons. 






There is no difference in incidence or location of AVMs in 
venous-specific and pan-endothelial Eng-iKO retinas sug-
gesting that loss of arterial ENG is not involved in driving 
the formation of AVMs. Instead, AVMs result from ENG 
defects in venous and/or capillary ECs. Furthermore, AVMs 
can form in the retinal primary plexus after the main neo-
angiogenesis events are complete and arteries have become 
muscularised. This finding suggests that AVMs are not 
restricted to areas of neo-angiogenesis, but can also occur 
in regions of vessel remodelling and maturation. We have 
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recently reported a similar scenario where aberrant remodel-
ling of mature peripheral vessels of the adult mouse leads to 
major AVMs following pan-endothelial ENG depletion [29]. 
Further work is required to determine whether loss of ENG 
in mature vessels leads to AVMs via reduced EC migration 
against flow, a process previously shown to underpin AVM 
formation in actively angiogenic vessels [13], or whether an 
abnormal increase in EC proliferation is the primary cause 
of AVMs in pre-established blood vessels.
Our work also helps to address a long-standing contro-
versy regarding whether AVMs form because of loss of arte-
rial identity. This idea has come from the fact that Notch sig-
nalling maintains arterial identity and loss of function Notch 
mutations lead to AVMs [16, 17]. Furthermore, Notch and 
ALK1 signalling activities synergise, in that SMAD1/5/8 
activity promotes transcription of Notch gene targets, such 
as those required for arterial identity. It has therefore been 
proposed that HHT may result from a loss of arterial identity 
due to reduced Notch activity. However, although crosstalk 
between Notch and Smad1/5/8 signalling is critical for the 
stalk cell phenotype [14] it does not appear that arteries 
play a direct role in AVM formation in HHT. We show here 
that even when arteries are unaffected, AVMs develop in 
the same way and at a similar frequency to pan-endothe-
lial depletion of ENG. This finding is in agreement with a 
venous and angiogenesis role for ENG, rather than an arte-
rial role, and is supported by the fact that ENG expression 
is stronger in veins and proliferating capillaries compared 
with arteries [13, 22]. We find the increased venous expres-
sion of ENG is maintained at P11, although ENG expression 
in the established capillaries of P11 retinas is now reduced 
below that of arteries (Supplementary Fig. 2b). Furthermore, 
we recently showed that the AVM phenotype in Eng-iKOe 
mouse retinas persists despite overexpression of human (h) 
Fig. 3  AVMs in Eng-iKOv reti-
nas are in the primary vascular 
plexus. a Depth coding images 
of isolectin stained control 
retinas at P11 (n = 20) allow dis-
crimination of the primary and 
deeper plexus. Colour spectrum 
scale denotes relative depth of 
focus with red corresponding 
to vessels closest to the retinal 
surface (primary plexus) and 
blue corresponding to the ves-
sels lying deeper in the retinal 
tissue. Separate Z stack images 
of the primary and deeper 
plexus are shown for compari-
son. b Depth coding analysis 
confirms that AVMs are located 
in the primary plexus of P11 
retinas (n = 16) harvested from 
Eng-iKOv neonates (following 
tamoxifen treatment at P5 and 
P6). Scale bar: 50 µm. A artery, 




ENG in arteries, and it was not until hENG was also over-
expressed in veins and capillaries that the AVM phenotype 
was rescued [13]. Our findings also align with recent work 
in zebrafish showing that Alk1 is not required for arterial 
identity, and AVM formation in alk1 mutants does not result 
from loss of Notch activity [30]. As the molecular role of 
ENG is to promote ALK1 signalling by facilitating ligand 
binding it is likely that ALK1, like ENG, will also not have 
an arterial role in protecting against AVMs in mammals, 
although supporting evidence currently awaits further stud-
ies. It is interesting to consider in this context our original 
observation that ENG expression is decreased in Alk1-iKOe 
retinas [12]. This raises the question of whether the reverse 
is true such that ALK1 expression is reduced in Eng-iKOe 
retinas. In fact, we observed that ALK1 expression appears 
to increase in the high flow AVMs of Eng-iKOe retinas 
using our previous knockout protocol [22] (Supplementary 
Fig. 3). These findings are entirely consistent with previous 
studies showing that ENG is downstream of BMP9 signal-
ling and is therefore be reduced in the absence of ALK1 
[12, 31], whilst in contrast, ALK1 expression has not been 
reported to be regulated by BMP9, but is upregulated by 
sheer stress [32, 33], which is anticipated to be increased due 
to the high blood flow through AVMs. Although endothelial 
loss of ENG or ALK1 lead to AVMs in preclinical models, 
the phenotype of ALK1-iKOe mutants is more severe than 
that of Eng-iKOe mutants [7]. This is likely because loss 
of ALK1, the signalling receptor, leads to elimination of 
this signalling pathway, whilst loss of ENG, the co-receptor, 
reduces the availability of ligand to the signalling receptor 
[3], thereby dampening rather than completely obliterating 
signal. In HHT patients, however, the differences between 
HHT1 (ENG) and HHT2 (ALK1) clinical phenotypes are 
more complex and await a better understanding of the rela-
tive contribution of second hits and additional factors such 
as inflammation to fully unravel the aetiology of this disease.
Finally, we show for the first time that AVMs can form in 
the murine retinal blood vessels during the second week of 
life, after the primary plexus is established, which consid-
erably extends the previous time frame available for these 
studies, opening up further options for therapeutic rescue 
experiments.
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